Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026

Reuters01-02

Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026

Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260102763645) on January 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2600068761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-02 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600068761","market":"us","top_or_hot":-1,"title":"Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260102763645) on January 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIronwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-02 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260102763645) on January 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL1KtNk0:1","article_id":"2600068761","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600068761","pubTimestamp":1767355517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药","BK4139":"生物科技"},"translate_title":"Ironwood Pharmaceuticals预计2026年调整后EBITDA将超过3亿美元","themeId":"b2d4671d65e4a3e3ea3a89bd362ecb9d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":0.9},"content_text":"Ironwood Pharmaceuticals Projects Over $300 Million Adjusted EBITDA for 2026\n    \n\n        Ironwood Pharmaceuticals Inc. has maintained its financial guidance for fiscal year 2025 and introduced its outlook for 2026, projecting significant growth in key performance metrics. For 2025, the company expects LINZESS U.S. net sales in the range of $860 million to $890 million, with total revenue between $290 million and $310 million, and adjusted EBITDA exceeding $135 million. Looking ahead to 2026, Ironwood forecasts a notable increase in LINZESS U.S. net sales to between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth. Total revenue is anticipated to rise to $450 million to $475 million, and adjusted EBITDA is projected to surpass $300 million, reflecting disciplined expense management and the positive impact of strategic initiatives.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260102763645) on January 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600068761","isCrawlerRequest":true}